Filtered By:
Management: National Institutes of Health (NIH)
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 769 results found since Jan 2013.
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial
Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The Phase 3 BLAZE-2 COVID-19 prevention trial - conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN) - enrolled residents and staff at skilled nursing and assisted living facilities, commonly referred to as nursing homes, across the U.S.
Source: World Pharma News - January 22, 2021 Category: Pharmaceuticals Tags: Featured Eli Lilly and Company Business and Industry Source Type: news
Africa: WHO Head Tedros Praises Resumed U.S. Commitment to Global Health Cooperation
[WHO] Geneva -- On Thursday 21 January, the day following the inauguration of President Joe Biden and Vice-President Kamala Harris, the leading U.S. infectious disease expert, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, officially participated for the first time in this week's meeting of the WHO Executive Board. WHO Director-General Dr Tedros Adhanom Ghebreyesus welcomed him - and praised the United States renewed engagement as a member sta
Source: AllAfrica News: Health and Medicine - January 21, 2021 Category: African Health Source Type: news
NIH officials highlight COVID-19 vaccine facts, unknowns for healthcare providers
(NIH/National Institute of Allergy and Infectious Diseases) Healthcare providers must be able to explain the latest data supporting the safety and efficacy of vaccines for coronavirus disease 2019 (COVID-19) so they can strongly encourage vaccination when appropriate while acknowledging that uncertainty and unknowns remain. This message comes from a new commentary co-authored by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and other leading NIAID scientists in the journalAnnals of Internal Medicine.
Source: EurekAlert! - Infectious and Emerging Diseases - January 18, 2021 Category: Infectious Diseases Source Type: news
NIH scientists identify nutrient that helps prevent bacterial infection
(NIH/National Institute of Allergy and Infectious Diseases) Scientists studying the body's natural defenses against bacterial infection have identified a nutrient--taurine--that helps the gut recall prior infections and kill invading bacteria, such as Klebsiella pneumoniae (Kpn). The finding, published in the journalCell by scientists from five institutes of the National Institutes of Health, could aid efforts seeking alternatives to antibiotics.
Source: EurekAlert! - Infectious and Emerging Diseases - January 15, 2021 Category: Infectious Diseases Source Type: news
Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine
January 13, 2021 -- Interim Phase 1/2a data were published today in the New England Journal of Medicine demonstrating that the Company’s single-dose investigational COVID-19 vaccine candidate (JNJ-78436735) – being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson – provided an immune response that lasted for at least 71 days, the duration of time measured in this study in participants aged 18-55 years. A preview of part of these interim data was posted on medRxiv in September 2020.The Phase 1/2a interim analysis showed that the Company’s COVID-19 vaccine candidate induced an immune respons...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!”
I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed.
This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news
Fueled by a History of Mistreatment, Black Americans Distrust the New COVID-19 Vaccines
When a COVID-19 vaccine becomes widely available to Americans, Brianna Clarke says she won’t be taking it.
“I don’t trust the vaccine,” the 22-year-old says. “I think it’s too soon to have a vaccine.” Clarke, who lives in Willingboro, N.J., is among a significant number of Black Americans who are skeptical of the healthcare industry in general and, critically, the COVID-19 vaccines recently developed by pharmaceutical companies Pfizer-BioNTech and Moderna, more specifically.
Over the past couple of weeks, the U.S. has averaged in the neighborhood of 200,000 new COVID-19 cases per d...
Source: TIME: Health - December 28, 2020 Category: Consumer Health News Authors: Dezimey Kum Tags: Uncategorized COVID-19 Source Type: news
Top Global Health Moments of 2020
By The Editorial Team,
IntraHealth International
Community Health Nurse Olivia Yeboah thoroughly washes her hands at the Akropong Clinic in Ghana. Photo by Emmanuel Attramah, PMI Impact Malaria/US President ' s Malaria Initiative.December 17, 2020If we wanted to, we could list a COVID-19 moment for every month of 2020. We all know that the onset of the coronavirus pandemic—first in China and then worldwide—overwhelmed news coverage this year. And with good reason. It’s the first large-scale global pandemic in 100 years. At the time this article was pu...
Source: IntraHealth International - December 17, 2020 Category: International Medicine & Public Health Authors: kseaton Tags: HIV & AIDS COVID-19 Nutrition Policy Advocacy Health Workforce Systems Nursing Midwifery 2020 Health Workers Source Type: news
Baricitinib plus Remdesivir shows promise for treating COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results published in The New England Journal of Medicine. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Medicine and Health - December 11, 2020 Category: International Medicine & Public Health Source Type: news
Genetically Engineered T Cells Could Lead to Therapies for Autoimmune Diseases
Digital media& downloads
Genetically Engineered T Cells Could Lead to Therapies for Autoimmune Diseases
UArizona immunobiologists have created a five-module chimeric antigen receptor T cell that is showing early potential to fight Type 1 diabetes.
Stacy Pigott
Today
University of Arizona Health SciencesNHG-111220-KUHNS-LAB_DSC9160-web.jpg
Michael Kuhns, associate professor in the Department of Immunobiology, and Shio Kobayashi, a post-doctoral research fellow, study the basic science of T cell activation in the immune system, and they are using that knowledge to find potential therapies for autoimmune diseases.
...
Source: The University of Arizona: Health - December 4, 2020 Category: Universities & Medical Training Authors: mittank Source Type: research
Vegan Condoms Helping Uk Allergy Suffers
Content
Diy Private Lubricant Recipes:
Details About Condom Additives
This Unbound Jelly Water
The Trendy Day Sex Package
Greatest Cbd Lube Bottles That You Could Purchase Right Now
My boyfriend and I used to make use of another lube, which I can’t recall proper now, that we would had to reapply every now and then. The very feel of it was cheesy, and the lube itself did not go very far. We go on common about forty five-60minutes, so we needed something that would sustain with us.
They recently released a brand new lube called BioNude, which works along with your physique to offer pure lubrication. Something cool I...
Source: Journal of Clinical and Aesthetic Dermatology - December 1, 2020 Category: Dermatology Authors: Buya Bat Tags: Uncategorized Source Type: research
2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group
The 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group was coordinated and supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. It is designed to improve patient care and support informed decision making about asthma management in the clinical setting. This update addresses six priority topic areas as determined by the state of the science at the time of a needs assessment, and input from multiple stakeholders:A rigorous process was undertaken to dev...
Source: Journal of Allergy and Clinical Immunology - December 1, 2020 Category: Allergy & Immunology Authors: Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), Michelle M. Cloutier, Alan P. Baptist, Kathryn V. Blake, Ed Tags: Reviews and feature article Source Type: research
NIH re-funds ACTG for the next seven years
(University of California - Los Angeles Health Sciences) The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, has been re-funded for the next seven years by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and collaborating NIH Institutes. The group is led by Judith Currier, M.D., M.Sc, Professor of Medicine at UCLA, and Joseph Eron M.D., Professor of Medicine, University of North Carolina. The Operations Center is based at UCLA.
Source: EurekAlert! - Infectious and Emerging Diseases - November 30, 2020 Category: Infectious Diseases Source Type: news
NIH announces restructured HIV clinical trials networks
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced the clinical investigators and institutions that will lead four NIH HIV clinical trials networks over the next seven years to conduct the innovative, efficient clinical research needed to accelerate progress against the HIV pandemic. NIAID also awarded grants to 35 U.S. and international institutions selected as HIV clinical trials units (CTUs).
Source: EurekAlert! - Infectious and Emerging Diseases - November 30, 2020 Category: Infectious Diseases Source Type: news
